Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2004 for Prevention of Venous Thromboembolism in Total Knee Arthroplasty
NCT06825416Phase 3Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SHR-2004 in venous thromboembolism (VTE) (3 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoints: Incidence of asymptomatic deep vein thrombosis (DVT) at Day 12 and Incidence of non-fatal pulmonary embolism (PE) at Day 12. Started Mar 2025; status: completed.
02
Drugs
SHR-2004
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06825416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825416.